🚀From Bench to Paper | New in Signal Transduction & Targeted Therapy: #Olverembatinib shows strong activity in #SDH-deficient #GIST (PFS ~26 months, CBR ~85%).
👍 The study used high-quality reagents (#bFGF, #hydrocortisone, #Infigratinib and #insulin) from MedChemExpress.

Consulta todos los detalles en nuestro artículo:

adee.es/actualizacio...

#Infigratinib #Acondroplasia #AvancesCientíficos

Oral Infigratinib Therapy in Children with Achondroplasia | NEJM Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1–3 selective t...

Super cool story of innovation and persistence in #NEJM. You might remember #infigratinib AKA #BGJ398, which recently lost FDA approval for FGFR2+ #cholangiocarcinoma. Low doses of #infigratinib are promising in a rare genetic skeletal condition #achondroplasia #medsky www.nejm.org/doi/full/10....

@US_FDA approves #Futibatinib for FGFR2+ Advanced #CCA. It’s been a great 2 years for BTC survivors with addition of #durvalumab + gem/cis as well as #ivosidenib (IDH1) #infigratinib #pemigatinib (FGFR2 fusion) #dabrafenib #trametinib (BRAF V600E)